BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $36.
BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $36.